P-173 - EVALUATION OF MORNING VERSUS EVENING DOSING OF IPATASERTIB, AN AKT INHIBITOR TO MITIGATE IPATASERTIB INDUCED GLUCOSE CHANGES.

D. Sutaria¹, P. Agarwal¹, S. Jones¹, D. Miles¹, J. Rotmensch¹, J. Gallo², G. Rasuo², H. Hinton², R. Sane¹; ¹Genentech, Inc., San Francisco, CA, USA, ²F. Hoffmann-La Roche, Basel, Switzerland.